News
CRITICARE, February 15-19, Pune, India
January 24 2012
Conference on Continuous Renal Replacement Therapies (CRRT), February 12-15, San Diego, USA
January 24 2012
MEDLAB, Arab Health, January 23-26, Dubai, UAE
January 16 2012
An addition to the Obesity and Type 2 Diabetes antibody portfolio
December 22 2011
Better kidney markers ahead?
December 05 2011
New NGAL.com website launched
November 24 2011
MEDICA, November 16-19, Düsseldorf, Germany
October 26 2011
ASN Kidney Week, November 8-13, Pennsylvania, Philadelphia, USA
October 20 2011
ESICM 2011, October 1-5, Berlin, Germany
September 06 2011
AACC Clinical Lab Expo, July 24-28, Atlanta
July 04 2011
BioPorto Diagnostics at the World Congress of Nephrology 2009, Milan, May 22-26
May 12 2009 by Ana Belén Enfedaque Buisán
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the International Society of Nephrology (ISN) join forces once more to organize the World Congress of Nephrology 2009 connecting renal professionals from around the world in order to share insights, create new approaches to research and therapy and advance global nephrology in general.
With over 450 speakers from more than 35 countries, the congress, which will be held in Hall 5 at Fiera Milano Congressi, combines the presentation of cutting edge research with a broad overview of the currently most relevant fields in the prevention, detection and treatment of kidney disease:
• CKD – epidemiology and consequences
• Aetiology and pathogenesis of kidney disease, clinical nephrology
• Hypertension and vascular disease
• Acute kidney injury
• Renal failure and dialysis
• Transplantation
A focus product for BioPorto Diagnostics is the renal biomarker NGAL, the leading biomarker for diagnosis of acute kidney injury (AKI). The early diagnosis of AKI is important, as it is associated with a high mortallity and and up to 50% of patients in intensive care may suffer some degree of acute kidney injury. NGAL determination is also highly relevant in nephrotoxicity and kidney transplantation. The NGAL product line from BioPorto Diagnostics includes ELISA kits for research and in vitro diagnostics as well as a wide selection of reagents for use in animal models which includes antibodies against human, mouse, rat, monkey, dog NGAL and the latest new addition of antibodies against pig NGAL.
Jakob Ohm Eriksen, NGAL pharma (clinical and preclinical) Product Manager and Klaus Boberg Pedersen, Human diagnostics (NGAL and MBL) Product Manager, will welcome you at booth no. A16. For more information or setting up an appointment, please contact them at joe@bioporto.com and kbp@bioporto.com respectively. Kristian Bangert, Head of Development, kb@bioporto.com, will participate in the scientific programme.
For further information on WCN 2009: www.wcn2009.org
